Copper ion treatments for dermatological areas of the body include solutions, creams, lotions, gets, foams, wound dressings, skin patches and suture material, each containing copper ions that bring about therapeutic effects when the copper ion treatments are applied to dermatological tissue. Methods of treating dermatological areas of the body include treatments for use on the skin and nails to treat conditions including disease, infection, inflammation, damaged or injured tissue, tissue needing to be sutured, rashes and other undesirable dermatological conditions.

The present invention provides synthetic fibres with advantageous properties such as high tensile strength and which can be produced by recombinant biotechnological means. The invention also provides the constituent components from which the fibres are assembled, along with fabrics formed from the synthetic fibres. Items comprising the fibres and fabrics of the invention are also included.

The present invention provides synthetic fibres with advantageous properties such as high tensile strength and which can be produced by recombinant biotechnological means. The invention also provides the constituent components from which the fibres are assembled, along with fabrics formed from the synthetic fibres. Items comprising the fibres and fabrics of the invention are also included.

Methods of treating a wound of a subject using a composition which includes graphene oxide (GO) and hyaluronic acid (HA) that are covalently linked, XAV939, and water. The composition can also include a surfactant, such as PEG. The composition can be topically administered to a subject to treat a wound of the subject.

A medical device includes a surgical needle attached to an elongated mesh suture. The suture is constructed of macroporous flat wall that facilitates and allows tissue integration into the suture core subsequent to introduction to the body, thereby preventing suture pull-through and improving biocompatibility.

A medical device includes a surgical needle attached to an elongated mesh suture. The suture is constructed of macroporous flat wall that facilitates and allows tissue integration into the suture core subsequent to introduction to the body, thereby preventing suture pull-through and improving biocompatibility.

A wound closure device can be provided as described herein. In an example, the wound closure device includes a first suture segment having a first suture configuration and a second suture segment having a second suture configuration. The first and second suture configurations can be different from each other. For example, the first suture configuration can includes a first set of characteristics such as barbed or non-barbed, barb sizes, filament sizes, colors, materials, and/or the like and the second suture configuration can include a second set of characteristics such as barbed or non-barbed, barb sizes, filament sizes, colors, materials and/or the like that can be different from the first set of characteristics. The wound closure device can further include connecting section configured to provide a transition from the first suture segment to the second suture segment.

An antimicrobial suture comprising a filament and taurolidine.

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.

An absorbable iron-based instrument is provided having an iron-based substrate, a zinc-containing protector in contact with the iron-based substrate, and a degradable polyester in contact with the iron-based substrate and/or the zinc-containing protector. The range of the ratio of the mass of the zinc-containing protector to the mass of the iron-based substrate is 1:200 to 1:2. In the degradable polyester, the mass fraction of a low-molecular-weight part with a molecular weight of less than 10,000 is less than or equal to 5%; alternatively, in the degradable polyester, the mass fraction of a residual monomer is less than or equal to 2%.